Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 27, 2003 (Fiscal Year 2004)
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems, including blood bank, red cell, surgical, and plasma collection products. The company operates as a single segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 27, 2003 |
3 Months Ended Dec 28, 2002 |
9 Months Ended Dec 27, 2003 |
9 Months Ended Dec 28, 2002 |
|---|---|---|---|---|
| Net Revenues | $90,737 | $87,115 | $266,508 | $256,075 |
| Gross Profit | $43,113 | $40,941 | $124,079 | $118,478 |
| Gross Margin | 47.5% | 47.0% | 46.6% | 46.3% |
| Operating Income | $14,096 | $11,822 | $31,188 | $31,340 |
| Net Income | $9,314 | $10,347 | $19,792 | $23,902 |
| Diluted EPS | $0.38 | $0.42 | $0.81 | $0.95 |
| Cash & Equivalents | $97,182 | $49,885 | $97,182 | $49,885 |
| Working Capital | $163,638 | $122,880 | $163,638 | $122,880 |
| Total Debt (Current + Long-term) | $66,576 | $70,617 | $66,576 | $70,617 |
Note: Working Capital calculated as Total Current Assets ($265,992) minus Total Current Liabilities ($102,354). Total Debt calculated as Notes payable/current maturities ($41,016) plus Long-term debt ($25,560).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 4.2% ($3.6M) for the quarter and 4.1% ($10.4M) for the nine months. Growth was driven by volume increases in Surgical, Blood Bank, and Red Cell disposables, partially offset by a decline in Plasma disposables and equipment sales.
- Profitability: Operating income increased 19.2% for the quarter due to cost reductions from the "CORE" program and lower R&D expenses. However, nine-month operating income decreased slightly ($0.2M) due to $2.7M in severance costs from a workforce reorganization.
- Net Income Decline: Net income decreased 10.0% for the quarter and 17.2% for the nine months. The nine-month decline was primarily due to a higher effective tax rate (36.0% vs. 24.3% prior year) and the absence of a $4.0M tax refund recorded in the prior year.
- Cash Flow: Operating cash flow improved significantly to $47.8M for the nine months (up from $29.3M), driven by reduced inventory investment and improved accounts receivable collection.
Guidance, Outlook, and Risks
- Alpha Therapeutic/Baxter Litigation: A significant risk involves the acquisition of Alpha Therapeutic by Baxter Healthcare. Baxter ceased purchasing Haemonetics' plasma products, leading to a $0.7M inventory reserve. Haemonetics filed for binding arbitration on January 21, 2004, seeking contract enforcement or damages.
- Reorganization: The company reduced its workforce by 4% (approx. 60 employees) in August 2003, incurring $2.7M in severance costs. Management is reviewing strategic initiatives which could lead to further asset impairments.
- Market Trends: The U.S. cell salvage market is mature and declining due to improved surgical techniques. Plasma markets face consolidation and excess supply. Conversely, Red Cell and Surgical (OrthoPAT) segments show growth.
- Foreign Exchange: Approximately 65% of sales are international. The company uses forward contracts to hedge currency risk. A weaker U.S. dollar generally benefits results; the current quarter saw favorable currency impacts.
- Tax Outlook: Management expects the effective tax rate to remain at approximately 36% for the remainder of fiscal 2004.
Investor Verification Checklist
- Plasma Segment Exposure: Verify the status of the arbitration against Baxter and the potential impact on future plasma revenue and inventory reserves.
- Reorganization Costs: Confirm if the $2.7M severance charge is fully recognized or if additional restructuring costs are anticipated.
- Equipment Sales Volatility: Monitor equipment sales trends, which are variable and heavily dependent on specific large orders (e.g., military, Japanese Red Cross) that may not recur.
- Foreign Currency Hedging: Review the effectiveness of hedging strategies given the high exposure to Euro and Japanese Yen fluctuations.
- Inventory Levels: Assess the adequacy of inventory reserves, particularly regarding the Alpha Therapeutic business line and excess/obsolete provisions.